GlaxoSmithKline, seeking to take advantage of just that, has announced a four year deal with 23andMe that allows them access to everyone’s genetic information for precisely the purposes pertaining to drug research.

Essentially, UK based GlaxoSmithKline, one of the world’s largest pharmaceutical ventures, just paid $300 million to sift through thousands upon thousands of genetic records of people who are primarily unaware or apathetic to the consequences of such activity.

https://prepforthat.com/23andme-signs-300-million-deal-with-glaxosmithkline/?fbclid=IwAR0hfuGfb9edzVk_D5bDnLZ4nHr0AiNNmcF6Nx0xs9FPYuWaAK6M59mUdTc